Clinical Therapies

Advaxis has three immunotherapy candidates currently in development: axalimogene filolisbac (AXAL) in HPV-associated cancers, ADXS-PSA in prostate cancer and ADXS-HER2 in HER2-expressing solid tumors, such as osteosarcoma, some breast cancers, esophageal and gastric cancer. Advaxis has a preclinical program with more than 20 distinct Lm Technology™ immunotherapies.

Advaxis will initiate a Phase 1 clinical trial of ADXS-NEO, the lead product candidate in the MINE™ program, in 2017 through a global collaboration with Amgen.

Clinical Pipeline